HER2-TARGETED THERAPIES

In a case-control study of women who developed cardiotoxicity while receiving HER2-targeted therapy for breast cancer and those who did not develop cardiotoxicity, adherence to cardiotoxicity surveillance guidelines (i.e., every-3-month left ventricular ejection fraction [LVEF] during therapy) was suboptimal, and there was no relationship between adherence to routine cardiac monitoring and heart failure.